Table 2 List of clinical trials included in the ORR analysis
From: Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
| Study | No. patients | ORR |
|---|---|---|
| CA209-067 |
n + i = 314 n = 316 |
n + i = 58.3% n = 44.6% |
| CA209-227 |
n + i = 396 n = 396 |
n + i = 35.9% n = 27.5% |
| IFCT-1501 MAPS2 |
n + i = 54 n = 54 |
n + i = 27.8% n = 18.5% |
| Alliance A091401 |
n + i = 38 n = 38 |
n + i = 15.8% n = 5.3% |
| CA209-032 (GastricCancer) |
n + i = 49* n + i = 52** n = 59 |
n + i = 24.5% n + i = 7.7% n = 11.9% |
| CA209-032 (BladderCancer) |
n + i = 196 n = 78 |
n + i = 34% n = 24% |
| CA209-032 (SCLC) |
n + i = 147 n = 95 |
n + i = 21% n = 12% |
